Tardive Dyskinesia Market Growth Driven by Emerging Therapies

The global tardive dyskinesia market is expected to experience significant growth during the forecast period of 2026–2036, registering a CAGR of 8.1%. The increasing prevalence of tardive dyskinesia, growing awareness among healthcare professionals, improved diagnosis rates, rising adoption of targeted therapies, and the development of innovative pipeline treatments are expected to contribute to market expansion. The introduction of emerging therapies such as NBI-1065890 (Neurocrine Biosciences), Bevantolol hydrochloride (SOM3355), LY03015 (Luye Pharma), ACP-271, SER-270, and TARDOXAL is anticipated to reshape the treatment landscape by addressing existing limitations associated with current therapies.

According to DelveInsight’s latest analysis, the Tardive Dyskinesia Market Insights report provides a comprehensive evaluation of current treatment practices, emerging therapies, market trends, competitive landscape, and forecasted market size across major markets, including the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover tardive dyskinesia latest treatments 2026 @ https://www.delveinsight.com/report-store/tardive-dyskinesia-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Tardive Dyskinesia Market Overview and Growth Outlook

The tardive dyskinesia market reached an estimated value of USD 4.4 billion across the 7MM in 2025. Among these regions, the United States represented the largest contributor, accounting for approximately 98% of the overall market share due to higher diagnosis rates, greater treatment adoption, and increased healthcare expenditure. The total prevalent population of tardive dyskinesia across the 7MM was estimated to be around 1.7 million cases in 2025.

The market is expected to witness continued growth as healthcare systems improve screening strategies and physicians gain greater awareness regarding movement disorders associated with long-term dopamine receptor-blocking therapies. Additionally, increasing investment in central nervous system (CNS) drug development is creating new opportunities for innovative treatment approaches.

Factors Supporting the Expansion of the Tardive Dyskinesia Market

One of the major factors driving market growth is the rising prevalence of tardive dyskinesia due to increased utilization of antipsychotic medications for conditions such as schizophrenia, bipolar disorder, and major depressive disorder. As the use of these medications continues globally, the number of patients at risk of developing TD is expected to increase. Improved disease recognition and diagnostic practices are also helping identify previously undiagnosed patients.

The increasing adoption of VMAT2 inhibitors has significantly transformed the treatment landscape. Currently approved therapies, including Valbenazine (INGREZZA) and Deutetrabenazine (AUSTEDO XR), have demonstrated effectiveness in reducing abnormal involuntary movements while maintaining psychiatric stability in many patients. Their clinical benefits and growing physician confidence are expected to support continued market growth.

The launch of emerging therapies is another important factor influencing future market dynamics. Novel candidates such as NBI-1065890, Bevantolol hydrochloride (SOM3355), LY03015, ACP-271, SER-270, and TARDOXAL are being developed with the objective of improving efficacy, tolerability, and patient adherence.

Aparna Thakur, Project Manager of Forecasting at DelveInsight, highlighted that although the pipeline remains limited, emerging therapies such as SOM3355 and novel GPR88 agonists may provide next-generation treatment options with improved selectivity and safety profiles.

Current Treatment Landscape and Unmet Needs in Tardive Dyskinesia

The current tardive dyskinesia treatment landscape is largely dominated by VMAT2 inhibitors, which represent the standard of care for managing symptoms. While these therapies have improved patient outcomes, they primarily provide symptomatic relief and do not reverse the underlying neurological changes associated with dopamine receptor hypersensitivity.

Underdiagnosis remains a significant challenge in the tardive dyskinesia market. Symptoms are often confused with psychiatric conditions, medication-related effects, or age-related movement changes, resulting in delayed treatment initiation. Increased screening and monitoring among patients receiving antipsychotic medications remain essential for improving diagnosis rates.

Existing treatments are also associated with certain limitations, including fatigue, somnolence, depression risk, akathisia, and cardiovascular concerns. These challenges highlight the need for safer and more effective therapies that can benefit patients who are unable to tolerate current treatments or experience inadequate symptom control.

Emerging Therapies Transforming the Tardive Dyskinesia Pipeline

The tardive dyskinesia pipeline consists of several promising candidates aimed at addressing current treatment gaps. Neurocrine Biosciences’ NBI-1065890 is an investigational oral VMAT2 inhibitor designed to regulate dopamine signaling and reduce abnormal involuntary movements. The therapy is currently being evaluated in Phase II clinical trials and represents one of the most advanced pipeline assets.

SOM Biotech’s SOM3355 (Bevantolol hydrochloride) is another promising candidate in Phase IIb development. The therapy utilizes a differentiated mechanism by combining β1-adrenergic receptor modulation with VMAT1 and VMAT2 inhibition. It is being investigated as a potential alternative with improved tolerability and reduced neuropsychiatric adverse effects.

Luye Pharma’s LY03015 is an innovative investigational therapy designed to inhibit VMAT2 while activating the sigma-1 receptor. The candidate is being developed for tardive dyskinesia and Huntington’s disease and represents a unique approach within the treatment landscape.

Acadia Pharmaceuticals’ ACP-271 is a small-molecule therapy currently in early-stage clinical development. The candidate aims to target neurological pathways associated with abnormal involuntary movements and improve treatment outcomes for patients with TD.

Discover more about which pipeline drugs could transform tardive dyskinesia treatment @ Tardive Dyskinesia Drugs - https://www.delveinsight.com/sample-request/tardive-dyskinesia-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Recent Developments in the Tardive Dyskinesia Market

Recent advancements indicate increasing innovation within the tardive dyskinesia treatment space. In May 2026, Neurocrine Biosciences presented real-world data demonstrating the functional impact associated with mild TD severity and improvements observed with valbenazine capsules.

In April 2026, Neurocrine Biosciences shared additional real-world evidence showing improved treatment persistence among adult TD patients receiving valbenazine compared with deutetrabenazine. During the same period, Luye Pharma Group initiated enrollment of the first participant in a US pharmacokinetic bridging study for LY03015.